소아천식 치료 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pediatric asthma treatment market size is projected to expand from USD 11.65 billion in 2025 and USD 12.38 billion in 2026 to USD 16.75 billion by 2031, registering a CAGR of 6.23% between 2026 to 2031.

This report is Segmented by Treatment Type (Long-Term Control Medications, and Quick-Relief Medications), Drug Class (Inhaled Corticosteroids, Long-Acting Beta Agonists, and More), Route of Administration (Inhaled, Oral, and Injectable), End User (Hospitals, Clinics, and Home Care), and Geography (North America, Europe, Asia-Pacific, and More). The Market and Forecasted in Terms of Value (USD).

Global Pediatric Asthma Treatment Market Trends and Insights

Rising Pediatric Asthma Prevalence and Earlier Diagnosis

Health agencies report a consistent pediatric asthma burden and persistent disparities, which continue to expand the treated pool within the pediatric asthma treatment market. Updated guidance now clarifies how to diagnose asthma in children under 5 by combining recurrent wheeze patterns, exclusion of other causes, and response to therapy, which moves intervention earlier and increases controller use. China's 2025 pediatric guideline reinforces inhaled corticosteroids as the foundation for reducing exacerbation risk and aligns clinic workflows around consistent controller access in the pediatric asthma treatment market. Longitudinal modeling for the Western Pacific Region projects continued increases in prevalence over the long term, which aligns with urbanization and allergen exposure patterns seen across the region. Routine biomarker use, such as FeNO and blood eosinophils, along with lung function testing from age 5, is becoming more common in outpatient settings, which supports earlier controller initiation and longer treatment duration. Together, these shifts support a stable base of multi-year therapy within the pediatric asthma treatment market.

Air Pollution and Respiratory Infections Elevate Exacerbations

The latest State of the Air report shows that 156.1 million people live in counties with unhealthy ozone or particulate levels, which sustains high rescue medication demand and emergency utilization for children in the pediatric asthma treatment market. EPA evidence links short-term PM2.5 exposure to higher asthma attack severity in children and documents chronic impacts on lung development, making exposure management a material clinical lever. These conditions reinforce the use of anti-inflammatory reliever strategies and controller intensification during high-risk seasons in the pediatric asthma treatment market. National pediatric guidance in China indicates that severe pediatric cases commonly report recurrent exacerbations despite standard therapies, a pattern that reflects environmental load and adherence gaps. Air quality improvements that reduce PM2.5, PM10, and nitrogen dioxide have documented benefits for pediatric respiratory health, which indicates that public health measures can lower exacerbation frequency over time. These dynamics keep a floor under reliever volume and sustain controller growth in the pediatric asthma treatment market.

High Cost and Payer Barriers for Advanced Therapies

US medical policies set rigorous conditions for pediatric biologics that require documented allergen sensitivity or biomarker criteria, demonstration of inadequate control on inhaled corticosteroids, recent pulmonary function testing, and evidence of improved outcomes to continue therapy, which slows time to treatment in the pediatric asthma treatment market. These requirements often introduce coordination across prescribers, specialty pharmacies, and assistance portals, which can add administrative friction for families. Several plan criteria include specific total IgE ranges for allergic phenotypes, proof of decreased rescue use, and improved FEV1 before renewal, which formalizes outcomes-based continuous-term utilization management on high-cost products. Manufacturers are addressing affordability with patient assistance programs and direct purchasing models that lower pricing on inhaled medicines and improve availability in the United States. Even so, access frictions remain a near term limiter on uptake across the pediatric asthma treatment market.

Other drivers and restraints analyzed in the detailed report include:

1. Guideline Shift to ICS-Containing Regimens Increases Controller Use
2. Pediatric Biologic Label Expansions and Access Programs
3. Safety Warnings and Side Effects Affecting Long-Term Use

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Long-term control medications held 58.47% in 2025, reflecting guideline-anchored daily ICS use and wider MART adoption, while quick relief options are projected to grow at 6.45% CAGR in 2026 to 2031 and controllers. Broader alignment around no SABA-only management and the use of low-dose ICS at baseline continues to support controllers as the bedrock of the pediatric asthma treatment market. The pediatric asthma treatment market benefits from clearer diagnostic pathways under age 5, which moves therapy earlier and lengthens time on controllers. National guidance in China also emphasizes ICS as the cornerstone for reducing acute risk, supporting the controller base in fast-growing APAC settings. Exacerbation volatility tied to pollution and viruses sustains rescue volumes even among treated children, which keeps quick relief options growing inside the pediatric asthma treatment market.

Quick relief growth also reflects structural demand from wildfire smoke events and urban air quality episodes, which intensify breakthrough symptoms and prompt swift treatment escalation. As MART use spreads, the boundary between controller and reliever blurs, since ICS formoterol serves both maintenance and as needed roles under current guidance. Action plans and technique training that improve adherence can moderate rescue use, but gaps remain in many primary care pathways, which maintains demand diversity in the pediatric asthma treatment market. Long term control medications that anchor role is likely to persist even as quick relief options post higher growth on environmental and seasonal dynamics.

Inhaled corticosteroids led with 34.73% in 2025 due to their efficacy to cost profile and central position across all treatment steps, while biologics are the fastest growing class with a 7.41% CAGR outlook to 2031. Guidance endorses low-dose ICS early and supports combination use for moderate disease, which stabilizes ICS volume in the pediatric asthma treatment market. Safety monitoring and step-down principles help contain high-dose ICS usage, creating opportunities for combinations and targeted options to share control in selected phenotypes. Biologic momentum reflects pediatric label expansions and the arrival of twice-yearly dosing, which aim to improve persistence and patient convenience in the pediatric asthma treatment market.

Biomarker-guided selection for Type 2 inflammatory asthma and improved access tools from manufacturers are supporting a steady rise in specialty use, while payers maintain rigorous criteria for coverage. The pediatric asthma treatment industry continues to balance high volume generics with low volume specialty products, a mix that defines margin trajectories for leading portfolios.

Geography Analysis

North America commanded 36.41% in 2025, reflecting high per capita spending and early adoption of biologics, while the Asia Pacific is the fastest-growing region at an 11.52% CAGR from 2026 to 2031. Guidance against SABA-only regimens and the emphasis on early ICS across primary care sustain controller use in the United States and Canada, which underpins the base of the pediatric asthma treatment market. Pollution-related exacerbations have intensified rescue patterns during wildfire seasons, adding volatility to short-term volumes. Payer policies with step edits and quantity limits moderate specialty adoption curves and keep coverage concentrated among well-documented severe cases.

Asia Pacific leads growth as urbanization and better access to specialists expand diagnosis and treatment, supported by national guidance that centers on ICS in pediatric care. Pediatric approvals for targeted therapies in China and earlier diagnosis criteria from global guidance support a steady shift toward phenotype-guided care in major urban centers. Device education and access to spacers and DPIs are improving but remain uneven across lower resource settings, which sustains a wide therapy mix in the pediatric asthma treatment market. As middle income coverage expands in large markets, controller adherence programs and school based pilots are poised to extend reach.

Europe sustains a significant share supported by national guideline alignment and technology appraisals for severe cases, while decarbonization policies reshape inhaler portfolios and tender dynamics. The EMA's support for low GWP propellants and associated device requirements are reshuffling manufacturing plans through this decade and temporarily favoring DPIs or soft mist devices in certain procurements. National health systems are also evaluating connected sensors for pediatric cohorts and assessing practical pathways to integrate adherence data into primary care workflows. Overall, Europe's combination of guideline adoption and sustainability transitions continues to support diversified portfolios in the pediatric asthma treatment market.

1. Amgen
2. AstraZeneca
3. Boehringer Ingelheim
4. Chiesi Farmaceutici
5. Cipla Limited B.V.
6. Covis Pharma
7. Dr. Reddy's Laboratories Ltd.
8. GlaxoSmithKline
9. Glenmark Pharmaceuticals
10. Hikma Pharmaceuticals
11. Lupin
12. Novartis
13. Orion
14. Regeneron Pharmaceuticals
15. F. Hoffmann-La Roche Ltd (Genentech, Inc.)
16. Sanofi
17. Sun Pharmaceuticals Industries
18. Teva Pharmaceutical Industries
19. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Pediatric Asthma Prevalence and Earlier Diagnosis
  • 4.2.2 Air Pollution and Respiratory Infections Elevate Exacerbations
  • 4.2.3 Guideline Shift to ICS-Containing Regimens Increases Controller Use
  • 4.2.4 Pediatric Biologic Label Expansions and Access Programs
  • 4.2.5 Smart Inhaler Adherence Programs in Schools and Primary Care
  • 4.2.6 At-Home Autoinjectors Enabling Home Dosing and Persistence
• 4.3 Market Restraints
  • 4.3.1 High Cost And Payer Barriers for Advanced Therapies
  • 4.3.2 Safety Warnings and Side Effects Affecting Long-Term Use
  • 4.3.3 Decarbonization-Driven pMDI Propellant Transition And Reformulation Drag
  • 4.3.4 Pediatric Inhaler Technique Variability Undermining Real-World Efficacy
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Treatment Type
  • 5.1.1 Long-term Control Medications
  • 5.1.2 Quick-relief Medications
• 5.2 By Drug Class
  • 5.2.1 Inhaled Corticosteroids
  • 5.2.2 Long-Acting Beta Agonists
  • 5.2.3 Leukotriene Receptor Antagonists
  • 5.2.4 Short-Acting Beta Agonists
  • 5.2.5 Long-Acting Muscarinic Antagonists Combination Inhalers
  • 5.2.6 Biologics
  • 5.2.7 Others
• 5.3 By Route of Administration
  • 5.3.1 Inhaled
  • 5.3.2 Oral
  • 5.3.3 Injectable
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Clinics
  • 5.4.3 Home Care
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)
  • 6.3.1 Amgen Inc.
  • 6.3.2 AstraZeneca PLC
  • 6.3.3 Boehringer Ingelheim International GmbH
  • 6.3.4 Chiesi Farmaceutici S.p.A.
  • 6.3.5 Cipla Limited B.V.
  • 6.3.6 Covis Pharma
  • 6.3.7 Dr. Reddy's Laboratories Ltd.
  • 6.3.8 GlaxoSmithKline plc
  • 6.3.9 Glenmark Pharmaceuticals Ltd.
  • 6.3.10 Hikma Pharmaceuticals PLC
  • 6.3.11 Lupin Limited
  • 6.3.12 Novartis AG
  • 6.3.13 Orion Corporation
  • 6.3.14 Regeneron Pharmaceuticals, Inc.
  • 6.3.15 F. Hoffmann-La Roche Ltd (Genentech, Inc.)
  • 6.3.16 Sanofi SA
  • 6.3.17 Sun Pharmaceutical Industries Ltd.
  • 6.3.18 Teva Pharmaceutical Industries Ltd.
  • 6.3.19 Viatris Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment